BioSpace News Archive

Lantern Pharma Inc. announced operational highlights and financial results for the third quarter ended September 30, 2023.

Cutera, Inc., a leading provider of aesthetic and dermatology solutions, provided preliminary financial results for the third quarter ended September 30, 2023, as well as recent business updates.

Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates.

Revance Therapeutics, Inc., reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it plans to make a public offering of $100.0 million of shares of its common stock, par value $0.01 per share, in an underwritten registered public offering.

ChromaDex Corp. announced financial results for the third quarter of 2023.

Certara, Inc., a global leader in biosimulation, reported its financial results for the third quarter of fiscal year 2023.

Catalyst Pharmaceuticals, Inc. reported financial results for the third quarter of 2023 and provided a corporate update.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to two employees outside Fusion’s 2020 Stock Option and Incentive Plan.

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2023 and filed its quarterly report on Form 10-Q for the three and nine months ended June 30, 2023 with the Securities and Exchange Commission.